Vantage logo

Argenx's big bid to stay ahead

A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.

Vantage logo

Cholesterol fears rock Immunovant

Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.